Grand Pharmaceutical Group Limited

Grand Journey for A Healthier World

Grand Pharma Announces 2021 Annual Results

The profit attributable to owners of the Company amounted to approximately HK$2,402.6 million, with an increment of approximately 34.0% as compared with same period in 2020.

Statement on Recent Fraudulent Use of the Commercial Name of Grand Pharma to Conduct Internet Financial Fraud

Corporate News

Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem

Corporate News

Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

Corporate News

The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry

Corporate News

Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum

Grand Journey for A Healthier World

Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem

Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum

Popular News

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

Yuanda medicine gets sepsis innovative medicine again

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

GP (HK) Announces 2019 Annual Results

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

Media Report

Yuanda medicine gets sepsis innovative medicine again